✦ LIBER ✦

Antiviral therapy for chronic hepatitis C: past, present, and future

✍ Scribed by Norio Hayashi; Tetsuo Takehara

Publisher: Springer Japan
Year: 2006
Tongue: English
Weight: 220 KB
Volume: 41
Category: Article
ISSN: 0944-1174
DOI: 10.1007/s00535-005-1740-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Antiviral treatment of chronic hepatitis

Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future

✍ Geoffrey Férir; Suzanne Kaptein; Johan Neyts; Erik De Clercq 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 227 KB

## Abstract A decade ago, standard therapy against chronic hepatitis B virus infections only consisted of lamivudine or IFN‐α. Treatment with lamivudine and IFN has been compounded by, respectively, the emergence of drug‐resistant virus strains and the appearance of serious side effects. In the las

First-line therapy for chronic myeloid l

First-line therapy for chronic myeloid leukemia: Past, present, and future

✍ Carolina Pavlovsky; Hagop Kantarjian; Jorge E. Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB

## Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard‐dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, pr

Antiviral treatment of hepatitis C: pres

Antiviral treatment of hepatitis C: present status and future prospects

✍ Kazuhiko Koike 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 283 KB

ChemInform Abstract: Antiviral Therapy f

ChemInform Abstract: Antiviral Therapy for Chronic Hepatitis C: Current Status and Perspectives

✍ Tetsuo Takehara 📂 Article 📅 2010 🏛 John Wiley and Sons ⚖ 15 KB 👁 2 views

Serum HBeAg quantitation during antivira

Serum HBeAg quantitation during antiviral therapy for chronic hepatitis B

✍ Heijtink, Rudolf A.; Kruining, Johannes; Honkoop, Pieter; Kuhns, Mary C.; Hop, W 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 2 views

Hepatitis Be antigen (HBeAg) seroconversion is considered the principal short-term goal of antiviral therapy in chronic hepatitis B. To test whether the pre-and per-treatment HBeAg quantitation has a higher predictive value than that of hepatitis B virus DNA (HBV-DNA) quantitation for the outcome of

Biotechnology for fuels: Past, present,

Biotechnology for fuels: Past, present, and future

✍ Don C Smith 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 70 KB

The aim then (as now) was to create a multidisciplinary meeting in which to consider research about and commercial applications for biotechnology. One of the long-term keys of the symposium was to establish a venue where academics, national laboratories, and industry would meet to consider the state